Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MCL1 | Q07820 | 16/20 | 0.78 |
| ▸ | HTR6 | P50406 | 2/20 | 0.57 |
| ▸ | HTR1A | P08908 | 1/20 | 0.55 |
| ▸ | DRD2 | P14416 | 1/20 | 0.55 |
| ▸ | DRD4 | P21917 | 1/20 | 0.55 |
| ▸ | HTR1D | P28221 | 1/20 | 0.55 |
| ▸ | HTR1B | P28222 | 1/20 | 0.55 |
| ▸ | HTR1F | P30939 | 1/20 | 0.55 |
| ▸ | HTR7 | P34969 | 1/20 | 0.55 |
| ▸ | DRD3 | P35462 | 1/20 | 0.55 |
| ▸ | BCL2 | P10415 | 2/20 | 0.54 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.52 |
| ▸ | MAPT | P10636 | 1/20 | 0.52 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15622460 | 0.98 | MCL1 (0.75) | MCL1HTR6HTR1ADRD2DRD4 | |
| SCHEMBL2208222 | 0.88 | MCL1 (1.00) | MCL1BCL2 | |
| SCHEMBL15622283 | 0.86 | MCL1 (0.96) | MCL1BCL2 | |
| SCHEMBL15622290 | 0.85 | MCL1 (0.76) | MCL1HTR6HTR1ADRD2DRD4 | |
| SCHEMBL15625853 | 0.84 | MCL1 (0.96) | MCL1 | |
| SCHEMBL15622705 | 0.83 | MCL1 (0.77) | MCL1HTR6HTR1ADRD2DRD4 | |
| SCHEMBL15622353 | 0.83 | MCL1 (0.75) | MCL1HTR6HTR1ADRD2DRD4 | |
| SCHEMBL17270357 | 0.83 | MCL1 (0.78) | MCL1HTR6HTR1ADRD2DRD4 | |
| SCHEMBL15622080 | 0.82 | MCL1 (0.79) | MCL1HTR6HTR1ADRD2DRD4 | |
| SCHEMBL15625757 | 0.82 | MCL1 (1.00) | MCL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10844032-B2 | Substituted benzofuran, benzothiophene and indole Mcl-1 inhibitors | VANDERBILT UNIVERSITY (US) | 2020-11-24 | — | — | US | disclosed |
| US-20180312485-A1 | SUBSTITUTED BENZOFURAN, BENZOTHIOPHENE AND INDOLE MCL-1 INHIBITORS | VANDERBILT UNIVERSITY | 2018-11-01 | — | — | US | disclosed |
| US-10093640-B2 | Substituted benzofuran, benzothiophene and indole MCL-1 inhibitors | VANDERBILT UNIVERSITY (US) | 2018-10-09 | — | — | US | disclosed |
| US-20150336925-A1 | SUBSTITUTED BENZOFURAN, BENZOTHIOPHENE AND INDOLE MCL-1 INHIBITORS | VANDERBILT UNIVERSITY (US) | 2015-11-26 | — | — | US | disclosed |
| EP-2134685-B1 | 7-NONSUBSTITUTED INDOLE DERIVATIVES AS MCL-1 INHIBITORS | ABBVIE INC (US) | 2015-09-02 | — | — | EP | disclosed |
| US-8853209-B2 | 1-oxyalkyl-2-carboxy-7-nonsubstituted indole derivatives | ABBVIE INC. (US) | 2014-10-07 | — | — | US | disclosed |
| WO-2014047427-A2 | SUBSTITUTED BENZOFURAN, BENZOTHIOPHENE AND INDOLE MCL-1 INHIBITORS | VANDERBILT UNIVERSITY (US) | 2014-03-27 | — | — | WO | disclosed |
| US-20110263599-A1 | 7-NONSUBSTITUTED INDOLE MCL-1 INHIBITORS | ABBOTT LABORATORIES | 2011-10-27 | — | — | US | disclosed |
| US-7981888-B2 | 1-oxyalkyl-2-carboxyl-7-nonsubstituted indole derivatives | ABBOTT LABORATORIES (US) | 2011-07-19 | — | — | US | disclosed |
| EP-2134685-A1 | 7-NONSUBSTITUTED INDOLE MCL-1 INHIBITORS | Abbott Laboratories (US) | 2009-12-23 | — | — | EP | disclosed |
| US-20090124616-A1 | 7-NONSUBSTITUTED INDOLE MCL-1 INHIBITORS | ABBOTT LABORATORIES (US) | 2009-05-14 | — | — | US | disclosed |
| WO-2008130970-A1 | 7-NONSUBSTITUTED INDOLE MCL-1 INHIBITORS | ABBOTT LABORATORIES (US) | 2008-10-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090124616-A1 | 7-NONSUBSTITUTED INDOLE MCL-1 INHIBITORS | MCL1, BCL2L1, API5 | MCL1 1/4885HTR6 1484/4885HTR1A 1791/4885 |
| US-20180312485-A1 | SUBSTITUTED BENZOFURAN, BENZOTHIOPHENE AND INDOLE MCL-1 INHIBITORS | MCL1, BCL2L1, BCLAF1 | MCL1 1/4885HTR6 1054/4885HTR1A 1279/4885 |
| US-20150336925-A1 | SUBSTITUTED BENZOFURAN, BENZOTHIOPHENE AND INDOLE MCL-1 INHIBITORS | MCL1, BCL2L1, BCLAF1 | MCL1 1/4885HTR6 1054/4885HTR1A 1279/4885 |
| US-10093640-B2 | Substituted benzofuran, benzothiophene and indole MCL-1 inhibitors | MCL1, BCL2L1, BCLAF1 | MCL1 1/4885HTR6 1054/4885HTR1A 1279/4885 |
| US-20110263599-A1 | 7-NONSUBSTITUTED INDOLE MCL-1 INHIBITORS | MCL1, BCL2L1, API5 | MCL1 1/4885HTR6 1484/4885HTR1A 1791/4885 |
| US-10844032-B2 | Substituted benzofuran, benzothiophene and indole Mcl-1 inhibitors | MCL1, BCL2L1, BCLAF1 | MCL1 1/4885HTR6 1054/4885HTR1A 1279/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.